XML 23 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss for the year $ (11,753) $ (5,313) $ (8,922)
Adjustments required to reflect the cash flows from operating activities:      
Effect of exchange rate differences on cash and cash equivalents balances 54 (251) (25)
Issuance expenses 517 242
Depreciation and amortization 342 278 280
Change in financial liabilities at fair value through profit or loss 1,891 (1,981) 513
Share-based payments 381 1,318 1,818
Exchange rate differences on restricted deposits balances 6
Capital gain (5)
Gain from cancellation of options to a group of investors (193)
Finance expenses in respect of financial liability to a group of investors 193
Recognition of day-one deferred loss 1,056
Listing expenses 1,545
Total adjustments 3,191 (399) 5,187
Changes in operating asset and liability items:      
Decrease (increase) in trade receivables (210) (138) 468
Increase in other receivables (68) (56) (83)
Increase (decrease) in trade payables (75) 134 (46)
Increase (decrease) in other payables 84 236 (22)
Decrease in deferred issuance expenses 61
Increase in deferred revenues and contract liabilities 34 191 101
Changes in operating asset and liability, total (174) 367 418
Net cash used in operating activities (8,736) (5,345) (3,317)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Restricted deposits (17) (36) (13)
Purchase of technology (308)
Proceeds from sale of property, plant and equipment 15
Purchase of property, plant and equipment (44) (132) (39)
Net cash used in investing activities (369) (153) (52)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from public and private offerings, net of issuance expenses 9,231 5,582 5,599
Israeli Innovation Authority, net 29 (26) (17)
Payment of loans and other financial liabilities (63) (2,178)
Deferred issuance expenses (61)
Proceeds from exercise of options and warrants 102 2,018 2
Cash acquired from reverse acquisition 317
Proceeds from financial liabilities and options 870
Net cash provided by financing activities 9,362 7,450 4,593
INCREASE IN CASH AND CASH EQUIVALENTS 257 1,952 1,224
EFFECT OF EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS (54) 251 25
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 3,514 1,311 62
CASH AND CASH EQUIVALENTS AT END OF YEAR 3,717 3,514 1,311
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:      
Classification to equity of series B warrants (see Note 13(e)) 3,479
Issuance of options to consultants (issuance costs) (23) (133)
Classification to equity of liability in respect to anti-dilution feature 1,787
Conversion of warrants into shares $ 348